SGLT2 Inhibitors Show New Promise
Recent advances in Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are showing improved glucose control and cardiovascular benefits for type 2 diabetes patients. Separately, Imeglimin is being highlighted as a "new ray of hope" for type 2 diabetes by targeting mitochondrial dysfunction and addressing both glucose metabolism and cellular energy pathways.
SGLT2 inhibitors were first approved by the FDA between 2012 and 2015 to lower plasma glucose in people with type 2 diabetes. Initially considered simply another option for glycemic control, their role in treatment has been substantially upgraded. This shift came after large clinical trials revealed unexpected and significant cardiovascular benefits. The cardiovascular advantages of SGLT2 inhibitors go beyond blood sugar control and include a reduced risk of cardiovascular death and hospitalization for heart failure. These benefits are now recognized as a class effect for drugs like empagliflozin and dapagliflozin. As a result, SGLT2 inhibitors are now recommended as a first-line treatment for heart failure by major cardiology societies. The mechanisms behind these cardiovascular benefits are thought to be multifaceted, involving blood pressure reduction, weight loss, and improved cardiac energy metabolism. They also reduce inflammation, mitigate oxidative stress, and improve the function of mitochondria. Imeglimin, the first in a new "glimin" class of oral medications, offers a different approach by targeting mitochondrial dysfunction, a core problem in type 2 diabetes. This unique mechanism improves the function of pancreatic beta-cells and enhances insulin action in the liver and muscles. By correcting defective cellular energy metabolism, Imeglimin addresses a root cause of type 2 diabetes. It has been shown to improve the way insulin is secreted in response to glucose and may help preserve the cells that produce insulin. The pivotal phase III clinical trial program for Imeglimin, known as TIMES, demonstrated its effectiveness in lowering glycated hemoglobin (HbA1c) with a favorable safety profile. This led to its first approval for use in type 2 diabetes in Japan in June 2021. Even with well-managed risk factors, adults with type 2 diabetes have a 21% higher risk of developing cardiovascular disease compared to the general population. People with type 2 diabetes are twice as likely to die from heart disease and stroke as those without the condition.
